BridgeBio Oncology Therapeutics Inc
bbotx.comWhat Do They Do?
Develops oral small-molecule therapies for cancers driven by RAS and related cell-growth signaling.
10-K for FY2025, filed Mar 5, 2026
Sources
How Are They Changing?
Since the FY2025 annual report
-
Sep 8, 2026
BBOT prioritized BBO-8520 and internal drug combinations
BBOT is focusing resources on BBO-8520 with pembrolizumab for inhibitor-experienced NSCLC and BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers.
Sources
8-K, filed Sep 8, 2026
BBO-11818 and BBO-10203 internal combination and independent combinations with standard of care agents in KRAS-mutant cancers.View ↗
-
Apr 23, 2026
Pedro Beltran became CEO, succeeding Eli Wallace
Beltran was appointed CEO and director; Wallace resigned from those roles and was expected to continue as an adviser.
Sources
8-K, filed Apr 23, 2026
On April 20, 2026, the Board of Directors (the “Board”) of BridgeBio Oncology Therapeutics, Inc. (the “Company”) approved the appointment…View ↗
Who Do They Compete With?
Competes with AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, Regeneron, Sanofi Genzyme, and Roche
10-K for FY2025, filed Mar 5, 2026
Sources
We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates…View ↗
Loading...
Comments
